𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Novel Therapies Targeting the Apoptosis Pathway for the Treatment of Acute Myeloid Leukemia

✍ Scribed by Aaron D. Schimmer

Book ID
107531999
Publisher
Springer
Year
2007
Tongue
English
Weight
231 KB
Volume
8
Category
Article
ISSN
1527-2729

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Advances in the treatment of acute myelo
Advances in the treatment of acute myeloid leukemia: From chromosomal aberrations to biologically targeted therapy
✍ Michael LΓΌbbert; Carsten MΓΌller-Tidow; Wolf-Karsten Hofmann; H. Phillip Koeffler πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 213 KB

## Abstract We describe several recent advances in our understanding and treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) including the use of cytogenetics to classify these diseases and to identify therapies that are specific for the abnormalities. Cell lines have provi

Progress in the treatment of acute myelo
Progress in the treatment of acute myeloid leukemia
✍ Farhad Ravandi; Alan K. Burnett; Edward D. Agura; Hagop M. Kantarjian πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 131 KB πŸ‘ 2 views

## Abstract Significant progress in understanding the mechanisms leading to the development of acute myeloid leukemia (AML) has led to the identification of numerous molecular abnormalities that may be responsible for leukemogenesis. Over the same period, large trials have established standard regi

Gemtuzumab ozogamicin in the treatment o
Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia
✍ Francis Giles; Elihu Estey; Susan O'Brien πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 484 KB πŸ‘ 2 views

## Abstract Gemtuzumab ozogamicin (GO) is a chemotherapeutic agent that consists of a humanized anti‐CD33 antibody (hP67.6) linked to N‐acetyl‐γ calicheamicin 1,2‐dimethyl hydrazine dichloride, a potent enediyne antitumor antibiotic. GO was approved conditionally by the Federal Drug Administration